Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Multiple Myeloma Clinical Trial

— IFM2016-03  

Official title:

Induction and Consolidation With Elotuzumab Before and After Peripheral Stem Cell Autologous Graft in Elderly Patients With Multiple Myeloma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03393273
• Other study ID #: P170103
• Secondary ID: 2017-001446-10
• Status: Withdrawn
• Phase: Phase 2
• Start date: February 20, 2018
• Est. completion date: January 15, 2019

Study information

• Verified date: July 2019
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label phase II study, assessing the efficacy of elotuzumab in elderly patients with multiple myeloma undergoing peripheral stem cell autologous graft

Description:

In patients of 65 years of age or older, intensive treatment (TI) with hematopoietic stem cell autologous graft (ASCH) is not considered as the gold standard. Nowadays, given the rise of new treatments, new studies assessing TI with ASCH in elderly, seem required. The association bortezomib (VEL) - thalidomide (THAL) - dexamethasone (DEX) is considered as the standard induction (Kumar, Flinn et al. 2012, Ludwig, Viterbo et al. 2013). However, more and more strategies with immunotherapies are developed. Furthermore, it looks encouraging to use several monoclonal antibodies at different clinical development levels. Thus, elotuzumab (ELO) is an IgG1 (immunoglobulin gamma-1) (IgGκ) humanized monoclonal antibody directed against SLAMF7. SLAMF7 is a glycoprotein expressed by myeloma cells and natural killer (NK) but not by healthy tissues. Consequently, elotuzumab can kill specifically myeloma cells without affecting healthy tissues (Hsi, Steinle et al. 2008). A phase I study assessed the safety of ELO in association with VEL, REV (Lenalidomide) and DEX in induction first-line treatment in elderly patients with median age of 67 years (Usmani, Sexton et al. 2015). There were no significant increase of side effects with this association compared with side effects usually reported with VEL, REV and DEX. Thus, adding ELO could lead to an increase of response rate, with no increase of toxicity.

For more than 10 years, the standard intensive treatment associates a MEL (MELPHALAN) conditioning (200 mg/m2) with a blood graft. In a recent study, almost all patients aged between 65-69 and 70-74 years received MEL at 200 mg/m2. The adverse events rate was similar between the different ages and a very low non-tied relapse mortality. Thus, in elderly patients selected, the use of MEL at 200 mg/m2 seems sure.

Moreover, it's widely admitted that the conditioning treatment should be based on an efficient drugs association with a limited toxicity. Studies assessing consolidation treatment with an association of new drugs are limited. Initial results suggest that the use of new drugs after intensive treatment (IT) with ASCH should increase response rate and improve progression-free survival and global survival.

The aim of this study IFM 2016-03 is to assess intensive treatment (IT) with AHSCT (Autologous hematopoietic stem cell transplantation) in elderly and to associate the different steps (induction, high dose conditioning, consolidation) with immunotherapy. Given the prior results of IFM and international studies, a VGPR (Very Good Partial Response) rate of around 85% is expected.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 15, 2019
• Est. primary completion date: January 15, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 66 Years and older

Eligibility

Inclusion Criteria:

• Multiple myeloma de novo.

• Stage DS (Durie-Salmon) : III, II, I with at least 1 symptomatic bone lesion (confirmed by radiology).

• Age > 65 years

• Indication for a first line treatment with induction, stem cell autologous graft and consolidation

• Available documentation including cytogenetic and International Staging System (ISS) of the initial diagnosis before inclusion,

• Effective contraceptive method for men with a partner of childbearing age during all the treatment period and within 6 months after the last cure

• Affiliated to social security

• Written informed consent

• Willingness and ability to respect the visits and all the demands required by the study

• Patient eligible to a high dose chemotherapy and fulfilling the following biological criteria :

• Neutrophils = 1,0 × 109/L

• Platelets = 75 ×109/L (platelets transfusions are not allowed within 3 days before inclusion)

• Total bilirubin = 1,5 × upper limit.

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 × upper limit

• Creatinin clearance > 50 mL/min

Exclusion Criteria:

• Diagnosis and treatment for any other cancer within five years before inclusion or any diagnosis for any cancer. Patients with a skin cancer (except melanoma or carcinoma in situ) are not excluded in case of complete resection.

• Central nervous system disease

• Infection requiring an intravenous (IV) antibiotherapy or any severe infection within 14 days before inclusion

• Diagnosis of any of the following diseases : Waldenström disease, POEMS (polyneuropathy, endocrinopathy, organomegaly, monoclonal gammapathy and skin lesions), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome or myeloproliferative disorder.

• Uncontrolled cardiopathy including : uncontrolled hypertension, uncontrolled heart arrhythmia, nonsymptomatic congestive cardiac failure, unstable angina or myocardial infarction within 6 months before inclusion

• Active infection with hepatitis B or C virus ; positive HIV serology

• Any comorbidity or severe concomitant disease incompatible with the patient inclusion or interfering with the safety assessment of the study treatments.

• Psychiatric history or any social condition limiting the patient compliance.

• Documented allergy to any studied treatment or any of their components.

• Disability to take oral treatments, inability or refusal to adhere to treatment constraints, or any digestive surgery interfering with oral absorption or treatment tolerance.

• Any experimental treatment within 30 days prior to the administration of the first dose of the studied treatmentParticipation to another clinical trial

• Prior participation to a clinical trial with elotuzumab, no matter the arm of treatment.

• Administration of any pharmaceutical speciality acting against myeloma - such as systemic corticosteroids (>10 mg of prednisone equivalent a day) or clarithromycin - within the month prior to the inclusion. In case of emergency, patients can receive dexamethasone (40mg/day, 4 consecutive days, maximum dose of 160mg) between screening and randomization

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Elotuzumab
Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21 melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21

Locations

Country	Name	City	State
France	Hématologie et thérapie cellulaire, Hôpital Saint Antoine	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria	Assesment of the International Myeloma Working Group uniform response criteria	1 month after the last consolidation cure
Secondary	survival and progression-free survival	Survival rate and global follow-up; Progression-free survival is defined as the duration between the beginning of treatment to the occurrence of a disease progression or death (whichever is the cause), according event occurring first.; Survival rate and global follow-up is defined as the duration between the start of treatment to death (whatever the cause).	one year after the last consolidation cure
Secondary	evaluation of the answer to the treatment to improve or maintain the response	Best response obtained or maintained for each therapeutical phase	12 month of treatment from inclusion
Secondary	Role of the consolidation phase in the improvement or maintenance of the response to the treatment Time before progression	Time before progression	From inclusion to month 36
Secondary	Conversion from negative residual disease to positive residual disease or maintenance of a negative residual disease during all therapeutical phases	Conversion rate from negative residual disease to positive residual disease or maintenance of a negative residual disease during induction,intensive treatment (IT) with AHSC (autograft of hematopoietic stem cells) and consolidation	from inclusion to month 36
Secondary	correlation between residual disease and duration of the response to the treatment	Comparison of response duration, overall survival and event-free survival between patients with negative residual disease and the other patients, after the induction phase and at the end of the treatment phase	From inclusion to the end of the 12 treatment-month
Secondary	Tolerance to each phase of treatment (the induction phase, the intensive treatment, the consolidation phase)	Tolerance to each therapeutical phase will be assessed with: ECOG (Eastern Cooperative Oncology Group) performance status; Adverse events rate, serious adverse events rate; Biological parameters (blood count and biochemistry)	From inclusion to month 36